Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Huron Consulting Group Inc. (HURN) is demonstrating robust operational execution, highlighted by a strong start to fiscal year 2026 with Q1 revenues before reimbursable expenses (RBR) growing 12.1% year-over-year to $443.7 million. The company's core healthcare and commercial segments continue to see resilient demand for complex consulting and managed services. Despite a mixed net income performance in Q1 due to a higher effective tax rate, adjusted EBITDA grew 21.9% to $50.6 million, and adjusted EPS of $1.73 beat consensus estimates. Backed by a record pipeline, strong backlog coverage, and aggressive capital return (repurchasing 6.5% of outstanding shares in Q1 2026 alone), Huron is well-positioned to meet its full-year 2026 guidance. The stock trades at an attractive valuation relative to its historical multiples and peers, presenting a compelling entry point.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026
Low · most bearish analyst$160.00
Mean target$190.75
High · most bullish analyst$215.00
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$160.00

Discretionary consulting spend softens due to macroeconomic headwinds, and client adoption of generative AI tools temporarily disrupts traditional consulting billing models. Margin expansion is pressured by rising labor costs and lower utilization rates, leading to full-year RBR and adjusted EPS landing at the low end of guidance ($1.78 billion and $8.35).

Base CaseCentral scenario
$190.75
Matches the consensus mean

Huron successfully executes its high single-digit organic growth algorithm, supported by steady pipeline conversion and stable utilization rates. EBITDA margins expand by approximately 50 basis points as guided, driven by operational efficiencies. Full-year 2026 RBR lands near the midpoint of guidance at $1.82 billion, with adjusted EPS of approximately $8.75.

Bull CaseUpside scenario
$215.00

Accelerated adoption of digital and AI-driven consulting solutions drives higher-margin engagements. Healthcare and education segments experience unprecedented demand due to regulatory changes and financial pressures, pushing full-year RBR and adjusted EPS to the high end of guidance ($1.86 billion and $9.15, respectively). Continued aggressive share buybacks further boost EPS growth.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Strong organic growth momentum, with Q1 2026 RBR up 12.1% (7.3% organic) driven by record performance in the healthcare segment.
  • Excellent backlog visibility, with management reporting a historically high backlog across the business supporting affirmed 2026 guidance.
  • Highly shareholder-friendly capital allocation, returning $155.5 million to shareholders via share repurchases in Q1 2026 alone.
  • Proven ability to expand margins, targeting a 50 basis point expansion in adjusted EBITDA margin for FY 2026.
Sign in / Sign up to read more
Key Investment Risks
  • Potential disruption from artificial intelligence on traditional consulting delivery models and billing structures.
  • Dependence on highly specialized talent, exposing the firm to wage inflation and recruitment/retention risks.
  • Sensitivity of discretionary consulting projects to broader macroeconomic downturns and corporate budget cuts.
Sign in / Sign up to read more
Thesis Invalidation Triggers
  1. A significant drop in consulting utilization rates or a contraction in the sales pipeline.
  2. Failure to achieve the guided 50 basis point adjusted EBITDA margin expansion due to cost overruns.
  3. A material slowdown in the healthcare consulting segment, which represents the company's largest revenue driver.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.